Two pathways are currently operating in Australian Gender healthcare:

Informed Consent and the Code of Conduct

Australian doctors and psychologists practise under binding codes of conduct issued by their regulators. For medical practitioners, that is Good Medical Practice: A Code of Conduct for Doctors in Australia, published by the Medical Board of Australia. For psychologists, the equivalent obligations sit within the Psychology Board's Code of Conduct and the APS Code of Ethics. These documents are not aspirational. They are the standard against which your practice will be assessed if a complaint is made, and they set the threshold below which conduct becomes professionally actionable.

This page sets out a structural problem that we believe has not been adequately considered in the current debate around gender-distressed young people: that the gender affirmation model of care, as currently practised in Australian clinics, fails to comply with the Code in at least ten distinct areas. Two of those failures are serious enough that they would, in any other area of medicine, attract regulatory attention on their own.

We have set this out in detail in our        Compliance Matrix ( which compares the standard medical model and the gender affirmation model section by section against Good Medical Practice.) What follows is the argument in summary, with the operative point for clinicians drawn out first.

​

The Vulnerability Inversion

The cohort of young people presenting to gender services has a profile that should trigger heightened clinical caution under standard practice. Published clinical data and the Cass Review's findings show high rates of co-occurring autism spectrum conditions, depression, anxiety, eating disorders, trauma histories, family disruption, and unresolved same-sex attraction. Each of these is, on its own, a recognised reason for slower differential diagnosis, careful exploration of underlying drivers, and conservative treatment thresholds. In combination, they describe a cohort to whom the profession's ordinary protective instincts should apply with unusual force.

Every other vulnerable cohort in Australian medicine is treated this way. Paediatric oncology, severe mental illness, cognitive impairment, dementia care, end-of-life decision-making - each attracts more procedural rigour, not less. Capacity is assessed more carefully. Consent processes are more thorough. The balance of benefit and harm is examined more cautiously. Treatments without robust evidence are withheld more readily.

The gender affirmation model inverts this. It treats heightened vulnerability as a reason to lower the evidentiary and consent thresholds, on the theory that any delay, scrutiny, or exploration of underlying conditions is itself harmful - sometimes framed as life-threatening. This inversion is the structural feature of the model that explains how otherwise careful clinicians find themselves practising in ways that would not pass scrutiny in any other area of their work.

​​

It is also the feature that puts the model in direct tension with the Code. The Code does not have an exception for cohorts whose advocates argue that the usual protections are themselves harmful. It requires what it requires, regardless of the political temperature around any particular patient group.

​

What the Code requires

The full compliance assessment is in the matrix. Two provisions are worth drawing out here because they are the most serious, and because most clinicians have not seen them framed this way.

Section 3.2.7 requires doctors to recommend treatments only where there is "an identified therapeutic need and/or a clinically recognised treatment, and a reasonable expectation of clinical efficacy and benefit for the patient." Multiple high-quality systematic reviews - Cass (2024), the York reviews, the US HHS review (2025) - have concluded that the evidence base for paediatric hormonal and surgical interventions is of low or very low quality, with unknown long-term outcomes and persistent uncertainty about benefit. Recommending those interventions despite that evidence base is not a contested clinical judgment. It is a direct compliance failure against 3.2.7.

Section 10.7.3 prohibits exploiting patients' vulnerability or fears about their future health, or raising unrealistic expectations. The framing routinely used to secure parental consent - most starkly, "would you rather a dead daughter or a living son?" - exploits parental fear about suicide risk to extract consent to interventions whose suicide-prevention claims are not supported by robust evidence. Promotional materials from gender clinics frequently promise authenticity, happiness, or lifesaving outcomes that the evidence does not support. This is a serious 10.7.3 violation, and it is the kind of conduct that, in any other clinical area, would draw the regulator's attention immediately.

The remaining eight areas of non-compliance - covering informed consent, capacity assessment in young people, balance of benefit and harm, disclosure of professional disagreement, honesty in medical reports, and adverse event monitoring - are set out in the matrix.

​

Why this Matters Now

The standard of care is shifting under the profession's feet. The Cass Review has been adopted as the basis for policy change in the UK. Sweden, Finland, Denmark, and other jurisdictions have moved away from routine medicalisation of paediatric gender distress. The systematic review literature has consolidated around evidence uncertainty. The detransitioner literature is growing. International medico-legal exposure is accumulating.

A clinician who today writes a referral, prescribes a hormonal intervention, or signs a letter supporting a young person's medical transition on the basis of an affirming intake may, in five or ten years, be defending that conduct against a negligence claim brought by an adult patient who was a child at the time. The Code violations set out in the matrix are precisely the kind of breaches that ground a finding of negligence. That is not a hypothetical risk. It is the legal landscape as it currently stands and as it is moving.

The purpose of this page is not to tell clinicians what to believe about gender. It is to make visible a regulatory reality that the current narrative around affirming care has obscured: that the Code applies, that it applies to this cohort with particular force, and that compliance with it is not optional.